Anavex Advances Drug Candidate for Treatment of Alzheimer’s Disease

Results from animal model testing demonstrate ANAVEX 1-41 has significant neuroprotective and anti-amnesic benefits Geneva, Switzerland — November 28, 2007 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) is pleased to announce promising developments with ANAVEX 1-41, the company’s lead drug candidate for Alzheimer’s disease. In recent pre-clinical animal studies, ANAVEX 1-41 prevented oxidative stress,…